SLT as primary therapy for POAG

Article

Effective at lowering pressure and repeatability make SLT first choice

Selective laser trabeculoplasty (SLT) has been applied in clinical practice since 2001. Before that time, the only laser surgery available to us that we could use in the chamber angle was argon laser trabeculoplasty (ALT). Compared with ALT, SLT is much better for the trabecular meshwork tissue and it has now completely eradicated the use of ALT. A number of studies in the literature comparing the two methods have demonstrated this.1

Fast, safe and effective method

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Subscribe Now!
Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
Related Content
Topcon Healthcare, Inc. appoints Krysten Williams Head of Digital Solutions & Clinical Development – EMEA

Topcon Healthcare, Inc. appoints Krysten Williams Head of Digital Solutions & Clinical Development – EMEA

Sydney M Crago
May 9th 2025
Article

Williams joins Topcon Healthcare from Heidelberg Engineering, where she held multiple senior leadership roles.

PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

July 25th 2024
Podcast

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

Tepezza receives marketing authorisation from MHRA

Tepezza receives marketing authorisation from MHRA

Kassi Filkins
May 8th 2025
Article

Teprotumumab is the first therapy specifically licensed for the treatment of moderate-to-severe thyroid eye disease in the UK

PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

July 24th 2024
Podcast

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

Isarna Therapeutics shares positive results from Phase 2 BETTER trial

Isarna Therapeutics shares positive results from Phase 2 BETTER trial

Sydney M Crago
May 7th 2025
Article
OPGX-LCA5 gene therapy phase 1/2 data support potential to restore meaningful vision

OPGX-LCA5 gene therapy phase 1/2 data support potential to restore meaningful vision

Lynda Charters
May 6th 2025
Article

Opus Genetics reveals promising 1-year results from OPGx-LCA5 gene therapy, showing sustained vision improvements in adults with LCA5 retinal degeneration.

© 2025 MJH Life Sciences

All rights reserved.